GC LabCell, which came out of a merger between the cell therapy
division of GC and the cord blood storage division of GCLabs,
focuses on its strategic tasks of researching and developing
natural killer (NK) cell-based immunotherapy agents and stem
cell-based treatments for rare diseases.
The company plans to expand its business into development of
more diverse stem cell-based treatments and a comprehensive
range of healthcare services for the global market.